Fairvoy Private Wealth LLC Purchases New Shares in AstraZeneca PLC (NASDAQ:AZN)

Fairvoy Private Wealth LLC acquired a new stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 4,606 shares of the company's stock, valued at approximately $302,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of AZN. McClarren Financial Advisors Inc. raised its position in shares of AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company's stock worth $25,000 after acquiring an additional 247 shares during the last quarter. Capital Performance Advisors LLP bought a new position in AstraZeneca during the 3rd quarter worth approximately $28,000. Albion Financial Group UT lifted its position in shares of AstraZeneca by 68.9% in the 4th quarter. Albion Financial Group UT now owns 608 shares of the company's stock worth $40,000 after purchasing an additional 248 shares during the period. Groupama Asset Managment boosted its stake in shares of AstraZeneca by 22.9% in the 3rd quarter. Groupama Asset Managment now owns 543,398 shares of the company's stock valued at $42,000 after purchasing an additional 101,225 shares during the last quarter. Finally, Ashton Thomas Securities LLC bought a new stake in shares of AstraZeneca in the 3rd quarter valued at $45,000. Institutional investors own 20.35% of the company's stock.

AstraZeneca Stock Up 0.1 %

Shares of NASDAQ AZN traded up $0.07 during trading on Tuesday, hitting $72.73. 5,338,836 shares of the company traded hands, compared to its average volume of 5,251,834. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. The business's fifty day moving average is $67.58 and its 200 day moving average is $73.52. The firm has a market capitalization of $225.54 billion, a price-to-earnings ratio of 32.18, a P/E/G ratio of 1.20 and a beta of 0.46. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68.

AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.10 by ($0.05). AstraZeneca had a return on equity of 32.55% and a net margin of 13.01%. Equities research analysts predict that AstraZeneca PLC will post 4.66 earnings per share for the current fiscal year.

AstraZeneca Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Monday, March 24th. Shareholders of record on Friday, February 21st will be paid a dividend of $1.03 per share. This represents a yield of 2%. The ex-dividend date is Friday, February 21st. This is a positive change from AstraZeneca's previous semi-annual dividend of $0.49. AstraZeneca's payout ratio is 43.36%.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. UBS Group upgraded shares of AstraZeneca from a "sell" rating to a "neutral" rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a "sell" rating to a "hold" rating in a research note on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.